Information for
Clinicians

Inclusion

Diabetic Kidney Disease (Type 1 or 2)

• eGFR 30-59mL/min/1.73m2 OR
• eGFR ≥ 60 with UPCR >150mg/g or UACR >30 mg/g

Diabetic Kidney Disease Resilient Individuals Inclusion Criteria

• ‍‍Type 1 diabetes for over 25 years
• Estimated glomerular filtration rate greater than or equal to 60 mL/min/1.73m2
• Urine albumin excretion less than 30 mg/d (or mg/g creatinine)

Hypertensive Kidney Disease

• eGFR30-59/min/1.73m2 with UPCR or UACR
• eGFR ≥ 60 with UACR 30-2000mg/g or UPCR 150-2000 mg/g

Acute Kidney Injury

• Baseline eGFR >45mL/min/1.73m2
• Elevated serum creatinine ≥1.5x baseline, AND one of the following:
• Further serum creatinine increase of 0.3 mg/dL
• Positive kidney injury urine biomarkers (NGAL, Kim1, TIMP2 x IGFBP7)
• Urine microscopy suggestive of ATN

Healthy Reference Groups

• Undergoing percutaneous nephrolithotomy for treatment of symptomatic renal stones without evidence of pyelonephritis
• Participating in a living donor kidney transplantation as the donor

‍

Exclusion

• Age (<18 years)
• Glomerular disease, Kidney transplant, Pregnancy
• Increased biopsy complication risk (Chronic anticoagulation, Platelets <100, INR>1.4, Hb <9, aspirin intake within 7 days of biopsy, Hypotension or BP that cannot be controlled to >160/100mmHg at time of biopsy).

‍

Study procedures

KPMP participants are asked to do the following:‍

• Have a biopsy of their kidney for research purposes.
• Give blood, urine and stool.
• Provide our study team with information about them.
• Talk to our study team 2-3 times a year for up to 10 years.

‍